文献速递前列腺癌

转移性激素敏感性前列腺癌中生活质量与疾病进展的关联:ARASENS与ARANOTE试验的启示

Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials.
PubMed 文献 · Eur Urol Oncol · 2026-04-08

该研究分析ARASENS和ARANOTE两项随机III期试验数据,探讨转移性激素敏感性前列腺癌患者生活质量的纵向变化及其与去势抵抗或死亡(CROD)和影像学进展或死亡(rPFS)的关联。结果显示达罗他胺组生活质量维持更优,生活质量下降与CROD率升高和rPFS缩短相关,且生活质量下降先于疾病进展。

要点

  • 达罗他胺治疗组生活质量维持优于安慰剂组。
  • 生活质量下降达到MID与CROD率升高及rPFS缩短相关。
  • 生活质量下降先于疾病进展,支持常规监测作为早期标志。

核心结论

  • 达罗他胺在改善CROD/rPFS的同时,生活质量维持优于安慰剂。
  • 生活质量下降先于疾病进展,支持常规生活质量监测作为疾病进展的早期标志。

研究设计与样本

  • 分析ARASENS(ADT+多西他赛±达罗他胺)和ARANOTE(ADT±达罗他胺)两项随机III期试验数据。
  • 采用联合模型关联生活质量与CROD(ARASENS)及rPFS(ARANOTE),并考虑信息性缺失。

主要发现

  • 达罗他胺组患者生活质量维持高于安慰剂组。
  • 生活质量下降达到MID与更高的CROD率相关(HR 2.58 [95% CI: 1.76-3.78])。
  • 生活质量下降达到MID与更短的rPFS相关(HR 1.32 [1.00-1.75])。
  • 基线生活质量更高与FACT-P测量的rPFS改善相关(HR 0.84 [0.76-0.92] per MID),但NCCN-FACT FPSI-17无明确关联(HR 0.95 [0.89-1.02])。
  • 联合模型提示达罗他胺的总效应主要由直接成分驱动,与生活质量维持相关的间接成分较小。

临床怎么用

  • 在mHSPC治疗中应常规监测生活质量,生活质量下降可作为疾病进展的早期预警信号。
  • 达罗他胺治疗可在改善临床结局的同时更好地维持生活质量。

局限性

  • 两项试验间疾病进展定义和生活质量评估工具(NCCN-FACT FPSI-17与FACT-P)存在差异,限制了解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maintaining quality of life (QoL) is an important treatment goal in metastatic hormone-sensitive prostate cancer (mHSPC). Evidence remains limited regarding longitudinal QoL changes, prognostic value, and contribution to treatment benefit. OBJECTIVE: We examined longitudinal QoL patterns, their association with castration resistance or death (CROD) and radiological progression or death (rPFS), and the contribution of QoL to the effect of darolutamide. DESIGN, SETTING AND PARTICIPANTS: We analyzed data from two randomized phase III trials: ARASENS (ADT + docetaxel ± darolutamide) and ARANOTE (ADT ± darolutamide). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: QoL was assessed using NCCN-FACT FPSI-17 (ARASENS) and FACT-P (ARANOTE). Joint models linked QoL with CROD (ARASENS) and rPFS (ARANOTE), accounting for informative missingness. RESULTS AND LIMITATIONS: Patients receiving darolutamide maintained higher QoL versus those receiving placebo. QoL decline meeting the minimally important difference (MID) was associated with higher CROD rate and shorter rPFS (HR 2.58 [95% CI: 1.76-3.78] and HR 1.32 [1.00-1.75], respectively). Higher baseline QoL was associated with improved rPFS for FACT-P (HR 0.84 [0.76-0.92] per MID) but no clear association was observed for NCCN-FACT FPSI-17 (HR 0.95 [0.89-1.02]). Joint modeling indicated that the total effect of darolutamide was largely driven by a direct component, with a smaller indirect component related to preserved QoL. Interpretation is limited by differences in disease progression definitions and QoL instruments between trials. CONCLUSIONS: Darolutamide improved CROD/rPFS while maintaining QoL better than placebo. QoL decline preceded progression, supporting routine QoL monitoring as an early marker of disease progression.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Morgans AK, Ekberg S, Boegemann M, et al. Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials. Eur Urol Oncol. 2026. PMID: 41956912. doi:10.1016/j.euo.2026.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。